Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-high trading volume on Wednesday . 937,938 shares were traded during trading, an increase of 296% from the previous session’s volume of 236,583 shares.The stock last traded at $22.4425 and had previously closed at $23.26.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Chugai Pharmaceutical Trading Down 4.8%

The business has a 50 day simple moving average of $24.17 and a two-hundred day simple moving average of $26.77. The stock has a market cap of $73.60 billion, a price-to-earnings ratio of 24.84 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Friday, April 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%.The company had revenue of $2.05 billion for the quarter. Research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.